CRISPR Therapeutics AG
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Crispr Therapeutics (CRSP) shares declined as investors took profits after a recent rally driven by positive clinical data and product rollout optimism. The company has no new catalysts, and sentiment shifts are causing volatility. Despite this, its CRISPR platform and pipeline may offer long-term value. However, the company remains unprofitable and faces cash burn challenges.
CRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.
Insiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CRSP (CRISPR Therapeutics AG). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent CRSP coverage spans financial news, technology and insider activity.
In the last 30 days, CRSP insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.4M). The most active reporter was KASINGER JAMES R., General Counsel and Secretary, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Profit‑taking pressure likely pushes the stock lower.
The upcoming presentation could move the stock depending on the safety and efficacy read‑out.
Slight downside risk as insider sell may raise concerns.
The piece highlights cash runway and upcoming data milestones but offers no new primary data, suggesting limited immediate price impact.
Insider sale may signal negative sentiment, modest pressure on CRSP stock.
AlphAI scores every news story that mentions CRSP with an AI model for sentiment and relevance, and aggregates insider trades from CRISPR Therapeutics AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Crispr Therapeutics (CRSP) shares declined as investors took profits after a recent rally driven by positive clinical data and product rollout optimism. The company has no new catalysts, and sentiment shifts are causing volatility. Despite this, its CRISPR platform and pipeline may offer long-term value. However, the company remains unprofitable and faces cash burn challenges.
1 min readCRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.
1 min readInsiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.
2 min readCRISPR Therapeutics (CRSP) is trading at $54.71, down 1.78%. The company has generated revenue from its approved CRISPR medicine but remains in R&D stage with fluctuating financials. Revenue spiked in 2021 due to a milestone payment, but normalized in subsequent years. Analysts have mixed opinions, with some seeing significant upside and others valuing the stock lower. The company has a strong cash position and several upcoming clinical trial catalysts.
2 min readKASINGER JAMES R. (General Counsel and Secretary) sold 10,400 shares of CRISPR Therapeutics AG (CRSP) at $60.24 ($0.63M total) on 2026-09-22 under a Rule 10b5-1 trading plan.
1 min readNovartis' Phase 3 trial for Pelacarsen showed it lowered lipoprotein(a) but failed to reduce major cardiovascular events. Citi suggests this may influence CRISPR Therapeutics' focus on CTX321 over CTX320, while Ionis Pharmaceuticals may see limited impact. Citi maintains Buy ratings for both companies with price targets of $88 for CRISPR and $100 for Ionis.
2 min readCRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) are compared for long-term investment potential. CRSP, a research-focused biotech, reported $3.5M revenue and a $581.6M net loss in FY 2025, while VRTX, an established pharmaceutical company, reported $12.1B revenue and a 32.7% net margin. CRSP trades at $55.76 with a negative P/E, and VRTX at $516.34 with a P/E of 30.04.
2 min readGene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.
2 min readCRISPR Therapeutics Director Ali Behbahani sold shares worth $780,935 on 2026-09-17 at an average price of $57.09 per share. Behbahani now directly owns 16,637 shares and indirectly owns 29 shares via the Behbahani Trust.
1 min readBehbahani Ali sold 13,679 shares of CRISPR Therapeutics AG (CRSP) at $57.09 ($0.78M total) on 2026-09-17.
1 min read
